Cyclophilin D: Guardian or Executioner for Tumor Cells?

Ling Zhang1*, Yi Liu1,2, Rou Zhou3, Baoyu He3, Wenjun Wang1 and Bin Zhang3,4*

1 School of Nursing, Jining Medical University, Jining, China, 2 School of Public Health, North China University of Science and Technology, Tangshan, China, 3 Department of Laboratory Medicine, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, China, 4 Institute of Forensic Medicine and Laboratory Medicine, Jining Medical University, Jining, China

Cyclophilin D (CypD) is a peptide-proline cis-trans isomerase (PPIase) distributed in the mitochondrial matrix. CypD regulates the opening of the mitochondrial permeability conversion pore (mPTP) and mitochondrial bioenergetics through PPIase activity or interaction with multiple binding partners in mitochondria. CypD initially attracted attention due to its regulation of mPTP overopening-mediated cell death. However, recent studies on the effects of CypD on tumors have shown conflicting results. Although CypD has been proven to promote the aerobic glycolysis in tumor cells, its regulation of malignant characteristics such as the survival, invasion and drug resistance of tumor cells remains controversial. Here, we elaborate the main biological functions of CypD and its relationships with tumor progression identified in recent years, focusing on the dual role of CypD in tumors.

Keywords: cyclophilin D, mitochondrial permeability transition pore, tumor energy metabolism, tumor cell death, tumor metastasis and invasion, tumor resistance

INTRODUCTION

Cyclophilin D (CypD) is a cyclophilin distributed in the mitochondrial matrix that acts as the gatekeeper of mitochondria (1, 2). Most previous studies considered that CypD plays a vital role in regulating cell apoptosis or necrosis by regulating mitochondrial permeability. Early studies on CypD were mostly limited to ischaemia-reperfusion injury, neurodegeneration, ageing, diabetes, etc (3–6). With the in-depth research on CypD function, the relationship between CypD and tumors...
has gradually become a research hotspot in recent years. It remains controversial whether CypD promotes or inhibits tumor progression. Many studies on the regulation by CypD of tumor cell survival, invasion and drug resistance have reported inconsistent conclusions. It has been reported that CypD can affect the malignant characteristics of tumor progression by regulating the bioenergetics and mitochondrial permeability of tumor cells. Here, we review the biological functions of CypD and its role in tumor progression. In particular, the question of whether CypD is the guardian of tumor progression or the executioner of tumor treatment is fully expounded upon this review.

CHARACTERISTICS OF CYPD

CypD is a peptide-proline cis-trans isomerase (PPIase) widely expressed in all mammalian tissues. CypD is encoded by the nuclear gene Ppid (located at 10q22-10q23), and its mRNA is 2,213 bases in length and encodes 207 amino acids (aa). After shearing, it is translocated to the mitochondrial matrix and transformed into a 178-aa mature peptide. CypD was originally named mitochondrial cyclophilin (CYP-M) and is now sometimes referred to as cyclophilin F or cyclophilin 3 (7). It should be noted, however, that CypD has been used in the past to refer to a 370-aa cytoplasmic cyclophilin protein encoded (7). It should be noted, however, that CypD has been used in the past to refer to a 370-aa cytoplasmic cyclophilin protein encoded by the Ppid gene. Under electron microscopy, CypD shows a spindle or rod structure with a diameter of 0.5-1.0 μm. CypD isomers are rarely reported.

The maintenance of normal mitochondrial permeability is critical to mitochondrial function and is mainly controlled by the status of the mitochondrial permeability transition pore (mPTP) (8, 9). mPTP, also known as the mitochondrial giant channel, is a calcium-dependent nonselective highly conductive channel. As early as the 1990s, CypD attracted attention due to its regulatory role in mPTP. The binding partners of CypD are mostly located in the mitochondrial inner membrane (MIM), including adenine nucleotide transporter (ANT), phosphate carrier (PiC), and oligomycin-sensitive binding protein (OSCP, a subunit of F1FO ATP synthase (complex V of OXPHOS)). At present, there are three hypotheses about the formation of mPTP by F1FO ATP synthase, namely, the c-ring hypothesis, “death finger” hypothesis and dimer/tetramer hypothesis (16) (Figure 1). The initiation signal of these three hypotheses is the mechanical combination of CypD and OSCP located in the crown of F1, but its downstream effect events are quite different (1): The c-ring hypothesis suggests that CypD-OSCP association induces the conformational changes in the F1 β subunit, decouples F1 and FO, and exposes the central hole of the c-ring to form mPTP (17) (2). The "death finger" hypothesis suggests that the mechanical force generated by CypD-OSCP association can be transmitted along the lateral stalk to the base of FO and remove the sealing effect of the 6.8PL subunit on the c-ring (18, 19) (3). The dimer/tetramer hypothesis also derives from CypD-mediated lateral stalk conformational changes, which allow adjacent e and g subunits on the dimer/tetramer to form mPTP together (20). It has been reported that the inhibition of the β subunit on the c-ring can be relieved even without Ca2+ overload. Therefore, the pore formed in the c-ring hypothesis is not true mPTP, but given that the formation of mPTP strictly requires Ca2+ for activation (21). In contrast, the status of mPTP in the other two hypotheses can be affected by Ca2+ concentration (22). The CypD-OSCP association not only induces conformational changes in F1FO ATP synthase to form mPTP, but also enhances the affinity of Ca2+ to the binding site on the β subunit, and significantly downregulates the Ca2+ threshold that makes mPTP open (23). If either hypothesis is true, it means that mPTP is located only in the MIM. This is also recognized by most researchers, and they believe that mPTP is actually a large nonselective channel formed in MIM, which is apparently different from the traditional definition of mPTP (8, 10).

However, the results of Carroll et al. cast doubt on the credibility of these three hypotheses (24). This is because the pore survives and can be induced to open by Ca2+ overload in mitochondria even after

THE MAJOR BIOLOGICAL FUNCTIONS OF CYPD

Regulation of Mitochondrial Permeability

mPTP is regarded as a key effector of cell death, where many signals that regulate cell death converge. The physiological and pathological roles of mPTP have been well studied, but its molecular identity and necessary regulatory factors remain controversial. mPTP was initially thought to be mainly composed of voltage-dependent anion channels [VDAC, located in the mitochondrial outer membrane (MOM)], ANT and CypD and is regulated by hexokinase II (HK II), PiC, mitochondrial creatine kinase (mtCK) and other proteins (9, 12) (Figure 1). However, with further research, the credibility of the classical mPTP model has been questioned in a series of genetic knockout studies (13, 14). In the absence of ANT or VDAC, increased Ca2+ still activates mPTP, and does not prevent cell death caused by mPTP overopening. These results suggest that CypD may also associate with other binding partners to promote mPTP opening and influence mitochondrial permeability. It is worth to mention that CypD is the only genetically proven indispensable mPTP component (15).

It has been reported that mPTP is more likely to be located in the F1F0 ATP synthase (complex V of OXPHOS). At present, there are three hypotheses about the formation of mPTP by F1F0 ATP synthase, namely, the c-ring hypothesis, “death finger” hypothesis and dimer/tetramer hypothesis (16) (Figure 1). The initiation signal of these three hypotheses is the mechanical combination of CypD and OSCP located in the crown of F1, but its downstream effect events are quite different (1): The c-ring hypothesis suggests that CypD-OSCP association induces the conformational changes in the F1 β subunit, decouples F1 and FO, and exposes the central hole of the c-ring to form mPTP (17) (2). The “death finger” hypothesis suggests that the mechanical force generated by CypD-OSCP association can be transmitted along the lateral stalk to the base of FO and remove the sealing effect of the 6.8PL subunit on the c-ring (18, 19) (3). The dimer/tetramer hypothesis also derives from CypD-mediated lateral stalk conformational changes, which allow adjacent e and g subunits on the dimer/tetramer to form mPTP together (20). It has been reported that the inhibition of the β subunit on the c-ring can be relieved even without Ca2+ overload. Therefore, the pore formed in the c-ring hypothesis is not true mPTP, but given that the formation of mPTP strictly requires Ca2+ for activation (21). In contrast, the status of mPTP in the other two hypotheses can be affected by Ca2+ concentration (22). The CypD-OSCP association not only induces conformational changes in F1F0 ATP synthase to form mPTP, but also enhances the affinity of Ca2+ to the binding site on the β subunit, and significantly downregulates the Ca2+ threshold that makes mPTP open (23). If either hypothesis is true, it means that mPTP is located only in the MIM. This is also recognized by most researchers, and they believe that mPTP is actually a large nonselective channel formed in MIM, which is apparently different from the traditional definition of mPTP (8, 10). However, the results of Carroll et al. cast doubt on the credibility of these three hypotheses (24). This is because the pore survives and can be induced to open by Ca2+ overload in mitochondria even after
the removal of different subunits of the c-ring or lateral stalk. Thus, they concluded that any form or component of F1FO ATP synthase was unlikely to form mPTP. The reason for this discrepancy may be that the purity, stability and functionality of F1FO ATP synthase may differ to varying degrees from those in vivo when isolated from mitochondria and reconstructed into extracorporeal membrane systems for independent study (19). Regardless of the specific location of mPTP, the excessive activation of the CypD-mPTP axis always triggers the permeability of MIM and MOM sequentially and ultimately initiates the cascade of cell death signals.

Additionally, the cell fate regulation by CypD is controversial. It has been suggested that CypD is a signalling molecule that promotes cell survival. This is because the overexpression of CypD delays the occurrence of mitochondrial membrane potential (MMP) collapse in HEK293 and B50 cells induced by oxidative stress and astrosporin, preserves the integrity of the mitochondrial membrane and promotes cell survival. This difference may be caused by the fact that PPIase activity is required for the protective effect of CypD, while the CypD-mediated mPTP opening is independent of PPIase activity. Thus, CypD may

**FIGURE 1** Schematic representation of the four mPTP models. When CypD is free in the mitochondrial matrix, mPTP is not activated and remains completely closed. The classical mPTP model holds that when CypD translocates from the matrix to the MIM and interacts with ANT, which can further induce the binding of ANT and VDAC to open the mPTP. The c-ring hypothesis suggests that conformational changes of F1 caused by CypD-OSCP association abolish the sealing effect of F1 on the c-ring, thereby promoting the central hole of the c-ring to form mPTP. Both the “dead finger” hypothesis and the dimer/tetramer hypothesis are caused by the conformation of the lateral stalk induced by the CypD-OSCP association, but the mPTP formation sites of the two are different. The former considers dissociating 6.8PL from c-ring to form mPTP, mPTP is formed by the lateral stalks of all F1FO ATP synthases that make up the dimer/tetramers. The former suggests that mPTP is activated by the removal of 6.8PL from the c-ring, while the latter suggests that mPTP is formed by the surrounding lateral stalks of all F1FO ATP synthases in the dimers/tetramers.
maintain physiological mitochondrial permeability and reverse the fate of apoptosis by binding to its binding partners other than ANT or F$_{1}$F$_{0}$ ATP synthase. The specific identity and regulatory mechanisms of the binding partners involved in CypD-mediated protection need to be further explored.

**Regulation of Mitochondrial Energy Metabolism**

It should be noted that F$_{1}$F$_{0}$ ATP synthase is also a key site for catalysing ATP production from ADP and inorganic phosphate (Pi). The conformation of the catalytic site on the β subunit can be altered when the protons generated by electron transport flows through the c-ring to drive ATP synthesis. The CypD-OSCP association not only induces the formation of mPTP, but also blocks the driving effect of the c-ring on F$_{1}$ and interferes with ATP metabolism (8, 25, 26). To improve energy metabolism efficiency, F$_{1}$F$_{0}$ ATP synthase also combines with ANT and PiC to assemble a bioactive unit with a molecular weight of at least 700,000, called the ATP synthasome (27, 28). Compared with wild-type mice, the formation of the ATP synthasome was enhanced in the heart mitochondria of CypD$^{-/-}$ mice, as well as in the brain and liver. In tissues with higher energy requirements (such as the heart and brain), F$_{1}$F$_{0}$ ATP synthase is more oligomerized, and CypD expression is lower (8). This is because CypD promotes the disassembly of the ATP synthasome and reduction to monomer or dimer forms, which is beneficial for mPTP opening. Therefore, no matter what the specific molecular nature of mPTP is, the regulatory role of CypD on mPTP opening cannot be overcome. The influences of the CypD-mPTP axis on mitochondrial permeability and energy metabolism modulate and promote each other, jointly determining cells fate.

CypD activity is regulated by posttranslational modifications (PTMs) on multiple specific residues (29–36). The same PTM at different residues or different PTMs at the same residue may have different effects on CypD activity, translocation and its ability to regulate mPTP opening (Figure 2). Additionally, CypD can bind to multiple direct or indirect binding partners in the mitochondrial matrix to activate or inhibit the CypD-mPTP axis, as described in the review by Porter et al. (7) (Figure 3).

**POSITIVE EFFECT OF CYPD ON TUMOR PROGRESSION**

**Promoting Tumorigenesis**

The oncogene Ras was reported to enhance CypD expression through the Raf-1/MEK/ERK pathway (37). Upregulated expression of CypD could antagonize the inhibitory effect of the p53-p21 pathway on tumor cell growth and induce Ras-mediated tumorigenesis. The study also found that the oncogenic activity of CypD is p53 dependent. Inhibition or knockout of CypD can effectively prevent Ras-dependent lung cancer and ErbB2-mediated breast cancer formation.

**Maintaining Aerobic Glycolysis**

Different from normal cells, tumor cells still have strong glycolysis activity and high acid metabolites even under the condition of adequate oxygen, which is known as the Warburg effect (38). The metabolic transition from OXPHOS to aerobic...
Glycolysis reduces the dependence of tumor cells on oxygen availability and is beneficial to the survival and invasion of tumor cells in the hypoxic microenvironment. The enhancement of glycolytic activity in tumor cells is closely related to irreversible damage to OXPHOS. The interaction between CypD and different components of the ATP synthasome can interfere with the progression of OXPHOS in tumor cells to a certain extent but does not cause ATP depletion. The initiation of aerobic glycolysis in tumor cells requires ATP produced by OXPHOS as the substrate, which is different from traditional anaerobic glycolysis (39). Hexokinase (HK), as the first rate-limiting enzyme of glycolysis, consists of four subtypes. It is worth noting that HK II is widely expressed in embryonic tissues and invasive tumors but is rarely expressed in normal tissues and only sparingly expressed in insulin-sensitive tissues (fat, muscle, heart) (40, 41). HK II can translocate from the cytoplasm to the MOM and bind with VDAC, which is called mitochondrial HK II (mtHK II) (42). MtHK II limits the movement of the N-terminal spiral of VDAC and keeps VDAC open. This ensures that ATP produced within the mitochondrial matrix is preferentially and continuously transported to mtHK II for aerobic glycolysis (43).

It has been reported that CypD overexpression can promote the formation of mtHK II, while inhibition or knockdown of CypD inhibits the level of HK II binding to the MOM (42, 44). Upregulated sirtuin 3 (SIRT3) was confirmed to inhibit the acetylation degree and PPlase activity of CypD and lead to the separation of CypD from ANT in breast cancer cells treated with oroxylin A (45). Simultaneously, the deacetylation of CypD triggered the dissociation of mtHK II from the MOM and inhibited the aerobic glycolysis activity of breast cancer cells. Similarly, ganoderic acid D (GAD) inhibited mtHK II formation and energy reprogramming in colon cancer cells by inducing SIRT3-mediated CypD deacetylation (46). Inhibition of SIRT3 activity effectively reversed mitochondrial cytotoxicity and reduced aerobic glycolysis induced by the abovementioned antitumor drugs. Intriguingly, overexpression of mutant CypD did not significantly change the level of mtHK II impaired by oroxylin A. Moreover, glioma cells expressing PPlase-deficient CypD were not effective against Bax-induced apoptosis compared to cells overexpressing wild-type CypD (47). Therefore, it is reasonable to assume that CypD relies on its PPlase activity to stabilize the association of ANT-VDAC-mtHK II.
An important question is why CypD-ANT binding is inconsistent in its dependence on PPIase activity in tumor and nontumor cells, which has been attributed to different ANT subtypes. There are four different subtypes of human ANT, including ANT1, ANT2, ANT3, and ANT4. Compared with the other three, ANT2 is widely expressed in rapidly growing cells, and only ANT2 can be highly induced in tumor cells (48, 49). The ANT2-VDAC-mtHK II association in tumor cells has been reported to play an important role in the maintenance of aerobic glycolysis and other carcinogenic effects (50, 51). Since ATP is continuously exported to the cytoplasm, it is not conducive to the maintenance of the essential intramitochondrial enzymatic pathways in tumor cells. Thus, mtHK II can reversely catalyse ATP production from G6P when the cytoplasmic ATP concentration reaches a certain threshold. Only ANT2 precisely allows ATP to be transported inwards into the mitochondrial matrix to maintain tumor cell survival and apoptotic resistance (52) (Figure 4). However, other ANTs, mainly located in nontumor cells, can continuously export mitochondrial ATP to the cytoplasm, which is detrimental to tumor cells with mitochondrial dysfunction. Given that the major ANT subtypes are different in tumor cells and nontumor cells, there may be discrepancies in the mechanisms that mediate CypD-ANT binding and the subsequent downstream effects.

Inhibiting Tumor Cell Apoptosis

Inhibition of tumor cell apoptosis is an important prerequisite and marker of tumorigenesis. CypD overexpression has been reported to attenuate apoptosis. As early as 2004, Schubert A et al. found that CypD was significantly upregulated in various tumors of reproductive tissues (breast, uterus and ovary) and inhibited apoptosis of tumor cells (11). This study found that CypD may attenuate the activation of mPTP triggered by other proapoptotic stimuli and the release of pro-apoptotic factors in a manner independent of PPIase activity, thus promoting tumor cell survival. Unfortunately, the protective mechanism of CypD on tumor cells was not specifically elucidated in this study. The formation of mtHK II is known to activate metabolic pathways

---

**FIGURE 4** | Schematic diagram of the mechanism of the CypD-ANT-VDAC-mtHK II association in the maintenance of aerobic glycolysis and mitochondrial function in tumor cells. Left: CypD-ANT1/3 association helps stabilize the binding of mtHK II to VDAC and thereby moderately activates mPTP, which ensures that ATP generated by OXPHOS can be preferentially and continuously transported to mtHK II for aerobic glycolysis. Right: conversely, mtHK II can reverse catalyse ATP production from G6P to maintain the essential intramitochondrial enzymatic pathways in tumor cells when the ATP concentration in the cytoplasm drops to a certain threshold. The maintenance of the latter process requires the CypD-ANT2-VDAC-mtHK II association.
such as aerobic glycolysis and pentose phosphate pathways to produce sufficient ATP and metabolic intermediates (such as NADPH) to rapidly provide energy and biosynthetic substrates for tumor cell growth and invasion. Furthermore, mtHK II can competitively bind VDAC with the proapoptotic factor Bax to inhibit the translocation of Bax to mitochondria, thus antagonizing Bax-mediated apoptosis (53, 54). Intriguingly, Machida et al. found that mtHK II formation is necessary for CypD to inhibit apoptosis of HeLa cells (human cervical cancer cell line) and C6 cells (rat glioma cell line), while PPIase activity is essential for CypD to stabilize mtHK II (47). This is inconsistent with the results of Schubert et al., which may be attributed to different tissue sources of tumor cells or diverse upstream signalling pathways that regulate CypD. In addition, the binding of CypD and Bcl-2 enhances the limiting effect of Bcl-2 on cytochrome C (Cyto C) release and improves the antiapoptotic effect of various tumor cell lines (human osteosarcoma cell line Saos2 and human acute leukemia cell line HL60) (55). Overexpression or knockdown of CypD can upregulate or downregulate the resistance of tumor cells to apoptotic stimulation, respectively (56). Coincidentally, downregulated miRNA-27b-3p in oral mucosal basal cells of patients with oral lichen planus (a typical precancerous lesion) also enhances the interaction of CypD-Bcl2, inhibits the release of proapoptotic factors and accelerates deterioration (57).

As previously mentioned, the association of CypD-ANT2-VDAC1-mtHK II contributes to mPTP opening to ensure either continuous ATP output for mtHK II utilization or ATP input for the maintenance of intramitochondrial enzymatic pathways. How do tumor cells avoid mPTP-mediated cell apoptosis or necrosis while maintaining the essential aerobic glycolysis through the CypD-mPTP axis? We hypothesize that the degree of mPTP opening for maintaining ATP and metabolic intermediates (such as ROS) is often used in tumor therapy. It has been reported that Akt2 abnormally activated by PI3K small molecule inhibitors (PI3Ki) in glioblastoma cells can translocate to mitochondria and subsequently phosphorylate CypD at S31 (61). Phosphorylated CypD supported mitochondrial bioenergetics, inhibited tumor cell apoptosis, and thereby mediated resistance to PI3K therapy. When combined with ganitritibib (a mitochondrial homeostasis inhibitor), PI3Ki effectively eliminated PI3K/Akt2/CypD pathway-mediated tumor resistance and significantly induced glioblastoma cell apoptosis.

**NEGATIVE EFFECT OF CYPD ON TUMOR PROGRESSION**

As shown in **Figure 5**, the role of CypD in tumor development is dual. Even for the same dimension of tumor development, CypD provoked by disparate upstream signals will exhibit bidirectional influence on tumors.

**Promotion of Tumor Cell Death**

As shown in **Figure 6**, most antitumor drugs can induce tumor cell necrosis by activating the CypD-mPTP axis (62–70). For example, ivermectin could induce necrosis of colon tumor cells, but not apoptosis, which is dependent on activation of the JNK

**Inducing Tumor Metastasis and Invasion**

p53 is a typical tumor suppressor gene. Different forms of p53 mutations can affect the tumor suppressor or transcriptional activity of p53 and may even promote tumor progression. TP53 truncating mutations are common in human tumors, especially TP53 exon-6 truncating mutations. p53 exon-6 truncating mutants are similar to the naturally occurring selective p53 splice variant (p53-psi), which lacks transcriptional activity and responds to DNA damage. However, they can translocate into mitochondria, bind to CypD and activate mPTP opening (58). Traditionally, mPTP opening suppresses mitochondrial function and triggers apoptosis. Interestingly, however, the CypD-mPTP axis activated by p53 exon-6 truncating mutants or p53-psi could promote tumorigenesis and present malignant features such as downregulation of E-cadherin expression. Likewise, p53ψ derived from the use of alternative 3’ splice site in p53 intron 6 could also enhance the motility and invasive capacity of multiple lung cancer and breast cancer cell lines by activating the CypD-mPTP axis (59).

Considering that the vast majority of p53 mutations that occur in human cancers are missense, the role of p53 missense mutants in regulating CypD is of interest to us. So far, only one article has mentioned both p53 missense mutants and CypD (60). It was found that mitochondrial wild-type p53 protein severely damaged the integrity of MOM and MIM by inducing the oligomerization of Bax, Bak and VDAC and the endogenous complex formation with CypD, respectively, thereby promoting the release of apoptotic factors. However, tumor-derived p53 missense mutants lost the ability to activate the Bax/Bak lipid pore. Unfortunately, the association between p53 missense mutants and CypD has not been further studied. Therefore, do missense mutations of p53 affect the association with CypD? If so, what are the downstream effects of this association? Are all or only some forms of p53 missense mutations associated with CypD? These seem to be very promising questions.

**Facilitating Tumor Resistance**

The phosphatidylinositol-3 kinase (PI3K) pathway is a convergence point that regulates cell proliferation, survival and bioenergetics and is often used in tumor therapy. It has been reported that Akt2 abnormally activated by PI3K small molecule inhibitors (PI3Ki) in glioblastoma cells can translocate to mitochondria and subsequently phosphorylate CypD at S31 (61). Phosphorylated CypD supported mitochondrial bioenergetics, inhibited tumor cell apoptosis, and thereby mediated resistance to PI3K therapy. When combined with ganitritibib (a mitochondrial homeostasis inhibitor), PI3Ki effectively eliminated PI3K/Akt2/CypD pathway-mediated tumor resistance and significantly induced glioblastoma cell apoptosis.
It was found that CypD-ANT1 association enhanced mPTP opening, resulting in increased mitochondrial depolarization and the release of lactate dehydrogenase into the cytoplasm. Indeed, CypD-ANT1 association was also involved in the therapeutic mechanisms of several other antitumor drugs (72–74). Furthermore, both bishonokiol A and 1, 2-Diarrachidonoyl-Sn-glycero-3-phosphoethanolamine (DAPE) upregulated CypD expression by activating the RIP1/RIP3/MLKL necrosis cascade, thus promoting mPTP-mediated necrosis of breast cancer and malignant pleural mesothelioma cells (75, 76). Similarly, bromocriptine could also promote the phosphorylation of CypD through the RIP3/MLKL pathway, thus inducing necrosis of prolactinoma cells (77). Moreover, CypD-p53 association has also been reported to be involved in the process of tumor cell necrosis induced by various antitumor drugs (78–83).

Moreover, CypD can also mediate the apoptosis process of tumor cells induced by antitumor drugs (84–93). For example, phosphorylated GSK3β is known to competitively bind ANT1 with CypD, thereby inhibiting mPTP opening. However, hirsutine dephosphorylated GSK3β in lung cancer cells through the ROCK1/PTEN/PISK/AKT pathway and activated the CypD-mPTP axis, thereby resulting in MMP decline, ATP dissipation, and caspase cascade-triggered apoptosis (94). Consistently, esculentin could activate the CypD-mPTP axis and induce apoptosis of gastric cancer cells by upregulating intracellular oxidative stress levels (69). In addition, tumor necrosis factor receptor-associated protein (TRAP1), a major member of the mitochondrial heat shock protein 90 (HSP90) family, can trap CypD in the TRAP1/HSP9/HSP60 multichaperone complex, thus limiting the translocation of CypD to the MIM. Treatment with HSP60 siRNA could promote the escape of CypD from the above complex, restore its activity and activate the excessive opening of mPTP, resulting in multiple tumor cell apoptosis (95). It should be noted that antitumor drugs do not induce just one type of cell death when treating a given tumor. For example, the enhanced association of p53-CypD-ANT1 led to both apoptosis and necrosis in non-small-cell lung cancer cells after treatment with ASP4132 (96). Inhibition or knockdown of CypD reversed cell necrosis induced by ASP4132 without affecting cell apoptosis. As mentioned above, the endogenous complex formed by wild-type p53 and CypD can participate in the destruction of MIM’s integrity. P53 is not only a typical tumor suppressor gene, but also regarded as a stress sensor that can sense multiple insults. For example, in response to oxidative stress during ischemia-reperfusion injury, p53 translocated into the mitochondrial matrix and triggered brain tissue necrosis by forming a robust complex with CypD (97).

In addition to the above two common forms of tumor cell death, CypD-induced autophagic cell death has been observed in liver cancer cells treated with andrographolide (98). This is because the activation of the CypD-mPTP axis by andrographolide leads to an increase in LC3 II and autophagosome in hepatoma carcinoma cells. Activation of CypD-mPTP axis is a common mechanism of tumor cell death induced by most antitumor drugs which is primarily achieved by upregulating the CypD-ANT1/3 association. As previously described, ANT1/3 can continuously export ATP into the cytoplasm, causing bioenergetic collapse of dysfunctional mitochondria in tumor cells and subsequently triggering cell death (99).
Attenuating Tumor Metastasis and Invasion

In contrast, Tavecchio et al. found that CypD expression was reduced or even lost in a variety of tumor cell lines (human glioma cell line LN229, human breast cancer cell line MCF-7 and human pancreatic cancer cell line MiaPACA), which could obviously activate interorganelle signalling and the pleiotropic inflammatory mediator STAT3 (100). On the one hand, activated STAT3 enhanced tumor cell proliferation by accelerating entry into S-phase. On the other hand, the Cxcl12-Cxcr4 association mediated chemokine-dependent autocrine/paracrine cell motility after CypD ablation, which was manifested as enhanced tumor cell migration and invasion. This finding indicates that CypD can inhibit tumor metastasis to some extent.

Suppressing Tumor Resistance

Wu et al. found that mortalin reduced mitochondrial permeability by blocking CypD-ANT3 binding and promoted the proliferation of human B-RafV600E melanoma cells and their resistance to vemurafenib (101, 102). Moreover, CypD expression and its association with mammalian sterile 20-like kinase 1 (MST1) were significantly downregulated, mediating gemcitabine resistance in pancreatic tumor cell lines (103). These data suggest that the association of CypD with its binding partners may be involved in the chemoresistance of some tumors.

CONCLUSIONS AND PERSPECTIVES

CypD is recognized as a gate that regulates cell fate and energy metabolism by many mechanisms. It has been demonstrated that CypD can affect tumor progression in multiple ways and seems to play a dual role in tumor cell fate (Table 1 and 2). CypD-mediated transient opening of mPTP helps regulate calcium homeostasis and attenuate ROS accumulation in mitochondria to maintain mitochondrial activity. Moderate levels of mPTP opening
TABLE 1 | Positive effect of CypD on tumor progression.

| Dimension                        | Upstream signal                          | Modulation of CypD                     | Outcome                                      | Tumor type                  | Reference |
|----------------------------------|------------------------------------------|----------------------------------------|----------------------------------------------|----------------------------|-----------|
| Tumorigenesis                    | Ras/Raf-1/MEK/ERK pathway                | CypD expression↑                       | Promotion of tumorigenesis and cell growth   | Lung cancer, Breast cancer | (37)      |
| Metabolic reprogramming          | SIRT3↓                                   | CypD acetylation, PPlase activity↑, CypD-ANT2-VDAC-mtHK II association | Promotion of aerobic glycolysis and maintenance of the essential intramitochondrial enzymatic pathways | Breast cancer, Colon cancer | (45, 46) |
| Tumor cell death                 | Unmentioned                              | CypD expression↑                       | Inhibition of pro-apoptotic factors release  | Tumors of reproductive tissues, Meningioma Colon cancer | (11, 56) |
| Unmentioned                      | SIRT3↓                                   | CypD acetylation, PPlase activity↑, CypD-ANT2-VDAC-mtHK II association | Inhibition of apoptosis                       | Colon cancer               | (46)      |
| Unmentioned                      | Unmentioned                              | PPlase activity↑                       | Induction of necrosis                        | Colorectal cancer           | (71)      |
| Tumor cell death                 | P38K/Akt2 p53 mutations                  | CypD phosphorylation (S31) association | Induction of apoptosis                       | Glioblastoma               | (61)      |
| Tumor metastasis and invasion    | P38K/Akt2                                | CypD phosphorylation (S31) association | Induction of apoptosis                       | Lung cancer, Breast cancer, Melanoma | (58, 59) |
| Tumor resistance                 | P38K/Akt2                                | CypD phosphorylation (S31) association | Promotion of motility and invasive capacity of tumor cells | Glioblastoma               | (61)      |

TABLE 2 | Negative effect of CypD on tumor progression.

| Dimension                        | Antitumor drug                           | Upstream signal                          | Modulation of CypD | Outcome                                      | Tumor type                  | Reference |
|----------------------------------|------------------------------------------|------------------------------------------|--------------------|----------------------------------------------|----------------------------|-----------|
| Tumor cell death                 | Hirsutine                                | ROCK1/PTEN/PI3K/GSK3β                    | CypD-ANT1 association | Induction of apoptosis                       | Lung cancer                | (94)      |
| GSK1595965                       | P38K/Akt2/ mTOR↓                         | CypD-ANT1 association                   | Induction of necrosis | Head and neck squamous cell carcinoma        | Non-small cell lung cancer, Prostate cancer | (72)      |
| ASP4132, AICAR                   | AMPK                                     | CypD-ANT1 association                   | Induction of necrosis | Non-small cell lung cancer, Prostate cancer | Colorectal cancer           | (73, 96) |
| Icaritin                         | JNK                                      | CypD-ANT1 association                   | Induction of necrosis | Non-small cell lung cancer, Prostate cancer | Colorectal cancer           | (71)      |
| Mortalin depletion               | MEK/ERK/ mTOR↓                           | CypD-ANT1 association                   | Induction of necrosis | B-Raf\(^{G13K}\) melanoma, KRAS tumor       | Hepatocellular carcinoma   | (74, 101) |
| Resminostat NPC-26, ABT-737, Curcin | Unmentioned                             | CypD-ANT1 association                   | Induction of necrosis | Non-small cell lung cancer, Prostate cancer | Pancreatic cancer, Melanoma  | (86-88)  |
| DN3                              | Unmentioned                              | CypD expression↑                        | Induction of apoptosis and cell cycle arrest | Gastric cancer              | Clear cell-renal cell carcinoma, Breast cancer | (89)      |
| Sorafenib                        | p-ERK↓                                   | CypD expression↑                        | Induction of apoptosis | Clear cell-renal cell carcinoma              | Clear cell-renal cell carcinoma, Breast cancer | (90)      |
| Bishonokol A                     | RIP1/RIP3/MLKL                           | CypD expression↑                        | Induction of necrosis | Clear cell-renal cell carcinoma              | Clear cell-renal cell carcinoma, Breast cancer | (75)      |
| Bromocriptine                    | RIP1/RIP3/MLKL                           | CypD phosphorylation                    | Induction of cell death | Prostate cancer, Lung cancer, Glioma, Pancreatic cancer, Colorectal cancer | Prostate cancer, Lung cancer, Glioma, Pancreatic cancer, Colorectal cancer | (78-83) |
| DAPE                             | RIP1/ERK                                 | Unmentioned                             | CypD-ermodin association | Malignant pleural mesothelioma               | Malignant pleural mesothelioma | (76)      |
| Emodin                           | AMPK                                     | CypD-ANT1 association                   | Induction of necrosis | Hepatocellular carcinoma                     | Hepatocellular carcinoma   | (91)      |
| O6-Docetaxel                     | AMPK, JNK, HER/ERK/Akt                   | Unmentioned                             | Inhibition of cell growth and induction of apoptosis | Breast cancer              | Breast cancer              | (92)      |
| Berberine, Doxorubicin, Salinomycin, Cisplatin, PF-543 | p53 association                      | CypD-p53 association                    | Induction of necrosis | Prostate cancer, Lung cancer, Glioma, Pancreatic cancer, Colorectal cancer | Prostate cancer, Lung cancer, Glioma, Pancreatic cancer, Colorectal cancer | (103)      |
| Gemcitabine                      | MST1                                     | CypD-MST1 association                   | Induction of necrosis | Prostate cancer, Lung cancer, Glioma, Pancreatic cancer, Colorectal cancer | Prostate cancer, Lung cancer, Glioma, Pancreatic cancer, Colorectal cancer | (103)      |

(Continued)
continuous provide substrates for aerobic glycolysis and essential intramitochondrial enzymatic pathways in tumor cells. The modestly activated CypD-mPTP axis can also promote the survival, metastasis and invasion of tumor cells. However, excessive mPTP opening inhibits the bioenergetics and malignant characteristics of tumor cells and triggers various forms of tumor cell death. This regulatory feature of the CypD-mPTP axis has been used to develop a variety of antitumor drugs. Therefore, the complex regulatory mechanisms of CypD make it a promoter of tumor progression, but also a weapon by which antitumour drugs may kill tumor cells (Figure 6). Rational utilization of the biological functions of CypD may make CypD a hot target for the treatment of various diseases, including tumors, in the future.

FUNDING

This study was supported by grants from the National Natural Science Foundation of China (No. 82173371), Tai Shang Young Scholar Foundation of Shandong Province (No.tsqp201909192) and Natural Science Foundation of Shandong Province (No. ZR2021QH294).

ACKNOWLEDGMENTS

The work was supported by the members of Zhang Lab, and I would like to show great gratitude to them all.

REFERENCES

1. Nicolli A, Basso E, Petronilli V, Wenger RM, Bernardi P. Interactions of Cyclophilin With the Mitochondrial Inner Membrane and Regulation of the Permeability Transition Pore, and Cyclosporin a-Sensitive Channel. J Biol Chem (1996) 271(4):2185–92. doi: 10.1074/jbc.271.4.2185
2. Scorrano L, Nicolli A, Basso E, Petronilli V, Bernardi P. Two Modes of Activation of the Permeability Transition Pore: The Role of Mitochondrial Cyclophilin. Mol Cell Biochem (1997) 174(1-2):181–4. doi: 10.1023/A:1006887921810
3. Teodoro JS, Varela AT, Duarte FV, Gomes AP, Palmeira CM, Rolo AP. Indirubin and Nad(+) Prevent Mitochondrial Ischaemia/Reperfusion Damage in Fatty Livers. Eur J Clin Invest (2018) 48(6):e12932. doi: 10.1111/eci.12932
4. Hafner AV, Dai J, Gomes AP, Xiao CY, Palmeira CM, Rosenzweig A, et al. Regulation of the Mptp by Sirt3-Mediated Deacetylation of Cypd at Lysine 23. doi: 10.1038/s41598-017-14795-x
5. Cui Y, Pan M, Ma J, Song X, Cao W, Zhang P. Recent Progress in the Use of Cyclophilin D to Delay Mitochondrial Membrane Matrix Permeability Transition Pore Opening in Cancer Res. (2004) 64(1):85–90. doi: 10.1158/0008-5472.can-03-0476-0
6. Naguib M, Abou Elfotouh M, Wafi MN. Elevated Serum Cyclophilin D Level Is Associated With Nonalcoholic Fatty Liver Disease and Higher Fibrosis Scores in Patients With Diabetes Mellitus. Int J Gen Med (2021) 14:4665–75. doi: 10.2147/ijgm.S322986
7. Porter GA Jr., Beutner G. Cyclophilin D. Somehow a Master Regulator of Mitochondrial Function. Biomolecules (2018) 8(4):176. doi: 10.3390/biom8040176
8. Beutner G, Alanzalon RE, Porter GA Jr. Cyclophilin D Regulates the Dynamic Assembly of Mitochondrial Atp Synthase Into Synthasomes. Sci Rep (2017) 7(1):14488. doi: 10.1038/s41598-017-14795-x
9. Cui Y, Pan M, Ma J, Song X, Cao W, Zhang P. Recent Progress in the Use of Mitochondrial Membrane Permeability Transition Pore in Mitochondrial Dysfunction-Related Disease Therapies. Mol Cell Biochem (2021) 476 (1):493–506. doi: 10.1007/s11010-020-03926-0
10. Bonora M, Paterngrini S, Ramaccini D, Morciano G, Pedriali G, Kahsay AE, et al. Physiopathology of the Permeability Transition Pore: Molecular Mechanisms in Human Pathology. Biomolecules (2020) 10(7):998. doi: 10.3390/biom1007998
11. Schubert A, Grimm S, Cyclophilin D. A Component of the Permeability Transition-Pore, Is an Apoptosis Repressor. Cancer Res (2004) 64(1):85–93. doi: 10.1158/0008-5472.can-03-0476
12. Jia K, Du H. Mitochondrial Permeability Transition: A Pore Intertwines Brain Aging and Alzheimer’s Disease. Cells (2021) 10(3):649. doi: 10.3390/cells10030649
26. Gauba E, Guo L, Du H. Cyclophilin D Promotes Brain Mitochondrial F1fo Atp Synthase Dysfunction Via Oxidative Stress. *J Ethnopharmacol* (2021) 270:13765. doi: 10.1016/j.jep.2021.13765

27. Wang X, Mao J, Zhou X, Li Q, Gao L, Zhao J. Thyroid Stimulating Hormone Triggers Hepatic Mitochondrial Stress Through Cyclophilin D Acetylation. *Oxid Med Cell Longevity* (2020) 2012:1249630. doi: 10.1155/2020/1249630

28. Sun T, Ding W, Xu T, Ao X, Yu T, Li M, et al. Parkin Regulates Programmed Necrosis and Myocardial Ischemia/Reperfusion Injury by Targeting Cyclophilin D. *Antioxidants Redox Signaling* (2019) 31(16):1177–93. doi: 10.1089/ars.2019.7734

29. Bibi SJ, Papapetropoulos A, Biodromitis EK, Daiber A, Randriamboavonjy V, Steven S, et al. Nitroglycerine Limits Infarct Size Through S-Nitrosation of Cyclophilin D: A Novel Mechanism for an Old Drug. *Cardiovasc Res* (2019) 115(3):625–36. doi: 10.1093/cvr/cvz222

30. Amanakis G, Sun J, Ferguson MM, McGinty S, Liu C, Molkentin JD, et al. Cysteine 202 of Cyclophilin D Is a Site of Multiple Post-Translational Modifications and Plays a Role in Cardioprotection. *Cardiovasc Res* (2021) 117(1):212–23. doi: 10.1093/cvr/cvaat53

31. Bigi A, Beltrami E, Trinet M, Stendardo M, Pellici PG, Giorgio M. Cyclophilin D Counteracts P53-Mediated Growth Arrest and Promotes Ras Tumorigenesis. *Cancer Res* (2018) 78(10):2978–88. doi: 10.1158/0008-5472.CAN-17-2830

32. Vaupel P, Schmidsberger H, Mayer A. The Warburg Effect: Essential Part of Metabolic Reprogramming and Central Contributor to Cancer Progression. *Int J Radiat Biol* (2019) 95(7):912–9. doi: 10.1080/09553002.2019.1589653

33. Luengo A, Li Z, Gui DY, Sullivan LB, Zagorulya M, Do BT, et al. Increased Demand for Nad(+) Relative to Atp Drives Aerobic Glycolysis. *Mol Cell* (2021) 81(4):691–707.e6. doi: 10.1016/j.molcel.2020.12.012

34. Wilson JE. Isozymes of Mammalian Hexokinase: Subcellular Localization and Metabolic Function. *J Exp Biol* (2003) 206(Pt 12):2049–57. doi: 10.1242/jeb.00241

35. Roberts DF, Miyamoto S. Hexokinase li Integrates Energy Metabolism and Cellular Protection: Acting on Mitochondria and Torcing to Autophagy. *Cell Death Differ* (2015) 22(2):364. doi: 10.1038/cdd.2014.208

36. Nederlof R, van den Elshout MAM, Koeman A, Uthman L, Koning I, Eerbeek O, et al. Cyclophilin D Ablation Is Associated With Increased Endo-Ismic Mammalian Hexokinase Activity. *Sci Rep* (2017) 7(1):12749. doi: 10.1038/s41598-017-13096-7

37. Shangguan X, He J, Ma Z, Zhang W, Ji Y, Shen K, et al. Sumoylation Controls the Binding of Hexokinase 2 to Mitochondria and Protects Against Prostate Cancer Tumorigenesis. *Nat Commun* (2021) 12(1):1812.

38. Giang AH, Raymond T, Brookes P, de Mesy Bentley K, Schwarz E, O’Keefe R, et al. Mitochondrial Dysfunction and Permeability Transition in Osteosarcoma Cells Showing the Warburg Effect. *J Biol Chem* (2013) 288(46):33303–11. doi: 10.1074/jbc.M113.507129

39. Wei L, Zhou Y, Dai Q, Qiao C, Zhao L, Hui H, et al. Oroxylin a Induces Dissociation of Hexokinase Ii From the Mitochondria and Inhibits Glycolysis by Sirt3-Mediated Decaptylation of Cyclophilin D in Breast Carcinoma. *Cell Death Dis* (2013) 4(4):e601. doi: 10.1038/cddis.2013.131

40. Liu Z, Li L, Xue B. Effect of Ganoderic Acid D on Colon Cancer Warburg Effect: Role of Sirt3/Cyclophilin D. *Eur J Pharmacol* (2018) 824:72–7. doi: 10.1016/j.ejphar.2018.01.026

41. Machida K, Ohta Y, Osada H. Suppression of Apoptosis by Cyclophilin D Via Stabilization of Hexokinase Ii Mitochondrial Binding in Cancer Cells. *J Biol Chem* (2006) 281(20):14314–20. doi: 10.1074/jbc.M513297200

42. Hubakovova S, Davidova E, Rohlenova K, Stursa J, Werner L, Andera L, et al. Selective Elimination of Senescent Cells by Mitochondrial Targeting Is Regulated by Ant2. *Cell Death Differ* (2019) 26(2):276–90. doi: 10.1038/s41418-018-0118-3

43. Li T, Li Y, Liu T, Hu B, Li J, Liu C, et al. Mitochondrial Pak6 Inhibits Prostate Cancer Cell Apoptosis Via the Pak6-Sirt4-Ant2 Complex. *Theranostics* (2020) 10(6):2571–86. doi: 10.7150/thno.42874

44. Chevrollier A, Leoiseau D, Chabi B, Renier G, Douay O, Malhîery Y, et al. Ant2 Isofrom Required for Cancer Cell Glycolysis. *J bienergetics biomembranes* (2005) 37(5):307–16. doi: 10.1007/s00865-005-8642-5
Zhang et al. CypD's Dual Role in Cancer

51. Shoshan-Barmatz V, Kedrin Y, Shteinfer-Kuzmine A. Vdac1 Functions in Ca (2+) Homeostasis and Cell Life and Death in Health and Disease. Cell Calcium (2018) 69:81–100. doi: 10.1016/j.cellcalc.2017.06.007

52. Zhao L, Tang M, Bode AM, Liao W, Cao Y, Ants and Cancer: Emerging Pathogenesis, Mechanisms, and Perspectives. Biochim Biophys Acta Rev Cancer (2021) 1875(1):188485. doi: 10.1016/j.bbcan.2020.188485

53. Pastorino JG, Shulga N, Hoek JB. Mitochondrial Binding of Hexokinase II Inhibits Bax-Induced Cytochrome C Release and Apoptosis. J Biol Chem (2002) 277(9):7610–8. doi: 10.1016/S0021-9258(02)00052-0

54. Cai J, Yi M, Tan Y, Li X, Li G, Zeng Z, et al. Natural Product Triptolide Induces Gsdme-Mediated Pyroptosis in Head and Neck Cancer Through Suppressing Mitochondrial Hexokinase-II. J Exp Clin Cancer Res (2021) 40(1):190. doi: 10.1186/s13046-021-01995-7

55. Eliseev RA, Malecki J, Lester T, Zhang Y, Humphrey J, Gunter TE. Mitochondrial Permeability Transition Pore Associated With Ros. Biochim Biophys Res Commun (2014) 452(4):768–74. doi: 10.1016/j.bbrc.2014.08.147

56. Zhou C, Chen Z, Lu X, Wu H, Yang Q, Xu D. Icaritin Activates Jnk-Dependent MtpP Necrosis Pathway in Colorectal Cancer Cells. Tumour Biol (2016) 37(3):3135–44. doi: 10.1007/s13277-015-4134-3

57. Xie J, Li Q, Ding X, Gao Y. Gsk3β95615 Kills Head and Neck Squamous Cell Carcinoma Cells Possibly Via Activating Mitochondrial Programmed Necrosis Pathway. Oncotarget (2017) 8(31):50814–23. doi: 10.18632/oncotarget.15135

58. Guo F, Liu SQ, Gao XH, Zhang LY. Aicar Induces Ampk-Independent Programmed Necrosis in Prostate Cancer Cells. Biochem Biophys Res Commun (2016) 474(2):277–83. doi: 10.1016/j.bbrc.2016.04.073

59. Wu PK, Hong SK, Starenki D, Oshima K, Shao H, Gestwicki JE, et al. Mortalin/Hgs9 Targeting Selectively Induces Kras Tumor Cell Death by Perturbing Mitochondrial Membrane Permeability. Oncogene (2020) 39(21):4257–70. doi: 10.1038/s41388-020-1285-5

60. Li HM, Li B, Ma H, Sun X, Zhu M, Dai Y, et al. Bishonokiol a Induces Multiple Cell Death in Human Breast Cancer Mcf-7 Cells. Asian Pac J Cancer Prev (2020) 21(4):1073–80. doi: 10.3322/aps.41387

61. Kaku Y, Tsuchiya A, Kanno T, Nakano T, Nishizaki T. Dararachidonoylprosthephanolamine Induces Necrosis/Necrotosis of Malignant Pleural Mesothelioma Cells. Cell signalling (2015) 27(9):1713–30. doi: 10.1016/j.cellsig.2015.07.007

62. Zhang SL, Tang HB, Hu JT, Zang ZL, Ding X, Li S, et al. Pgam5-Cytopathology Is Involved in Bromocriptine-Induced Ripl3/Mdk-Dependent Necrosis of Prolactinoma Cells. Biomed pharacother (2019) 111:638–48. doi: 10.1016/j.biopha.2018.12.128

63. Zhang LY, Wu YL, Gao XH, Guo F. Mitochondrial Protein Cytoplasm-D-Mediated Programmed Necrosis Attributes to Berberine-Induced Cytotoxicity in Cultured Prostate Cancer Cells. Biochem Biophys Res Commun (2014) 440(1):697–703. doi: 10.1016/j.bbrc.2014.06.039

64. Lu JH, Shi ZF, Xu H. The Mitochondrial Cyclophilin D/P53 Complex Mediates Doxorubicin-Induced Non-Apoptotic Death of A549 Lung Cancer Cells. Mol Cell Biochem (2016) 398(1-2):17–24. doi: 10.1007/s11010-015-2212-2

65. Qin LS, Jia PF, Zhang ZQ, Zhang SM. Ros-P53-Cyclophilin-D Signaling Mediates Salinomycin-Induced Glisicna Cell Necrosis. J Exp Clin Cancer Res (2015) 34(1):57. doi: 10.1186/1475-2863-34-151

66. Chen B, Xu M, Zhang H, Wang JX, Zheng P, Gong L, et al. Caspatin-Induced Non-Apoptotic Death of Pancreatic Cancer Cells Requires Mitochondrial Cyclophilin-D-P53 Signaling. Biochem Biophys Res Commun (2013) 437(4):526–31. doi: 10.1016/j.bbrc.2013.06.103

67. Yu T, Gao D, Fang ZY. Targeting Colorectal Cancer Cells by a Novel Sphingosine Kinase 1 Inhibitor Pf-543. Biochem Biophys Res Commun (2014) 437(3):728–34. doi: 10.1016/j.bbrc.2013.05.007

68. Wu L, Cao K, Ni Z, Wang S, Li W, Liu X, et al. Rhein Reverses Doxorubicin Resistance in SMMC-7721 Liver Cancer Cells by Inhibiting Energy Metabolism and Inducing Mitochondrial Permeability Transition Pore Opening. Biofactors (2019) 45(1):85–96. doi: 10.1002/biof.1462

69. Peng X, Zhang D, Li Z, Fu M, Liu H. Mitor Inhibition Sensitizes Human Hepatocellular Carcinoma Cells to Resminostat. Biochem Biophys Res Commun (2016) 474(4):556–62. doi: 10.1016/j.bbrc.2016.06.060

70. Fu M, Shi W, Li Z, Liu H. Activation of MtpP-Dependent Mitochondrial Apoptosis Pathway by a Novel Pan Hdc inhibtor Resminostat in Hepatocellular Carcinoma Cells. Biochem Biophys Res Commun (2016) 474(4):527–33. doi: 10.1016/j.bbrc.2016.04.147

71. Dong YY, Zhang YH, Cai WJ, Liu Y, Zou WB. The Mitochondrion Interfering Compound Npc2-Exerts Potent Anti-Pancreatic Cancer Cell Activity in Vivo and in Vivo. Tumour Biol (2016) 37(11):15053–63. doi: 10.1007/s13277-016-5403-5

72. Yu T, Chen C, Sun Y, Sun H, Li TH, Meng J, et al. Abt-737 Sensitizes Curcumin-Induced Anti-Melanoma Cell Activity Through Facilitating MtpP Death Pathway. Biochem Biophys Res Commun (2015) 464(1):286–91. doi: 10.1016/j.bbrc.2015.06.044

73. Qiu Y, Yu T, Wang W, Pan K, Shi D, Sun H. Curcumin-Induced Melanoma Cell Death Is Associated With Mitochondrial Permeability Transition Pore (MtpP) Opening. Biochem Biophys Res Commun (2014) 448(1):15–21. doi: 10.1016/j.bbrc.2014.04.024
89. Ma YC, Zhu YL, Su N, Ke Y, Fan XX, Shi XJ, et al. A Novel Ent-Kaurane Diterpenoid Analog, Dn3, Selectively Kills Human Gastric Cancer Cells Via Acting Directly on Mitochondria. *Eur J Pharmacol* (2019) 848:11–22. doi: 10.1016/j.ejphar.2019.01.013

90. Hu W, Yuan Q, Liu XH, Zhu HC, Lv SQ, Wang XH. Cyclophilin D-Mediated Apoptosis Attributes to Sorafenib-Induced Cytotoxicity in Clear Cell-Renal Cell Carcinoma. *Eur J Pharmacol* (2015) 749:142–50. doi: 10.1016/j.ejphar.2014.12.025

91. Zhang L, He D, Li K, Liu H, Wang B, Zheng L, et al. Emodin Targets Mitochondrial Cyclophilin D to Induce Apoptosis in Hepg2 Cells. *Biomed Pharmacother* (2017) 90:222–8. doi: 10.1016/j.biopha.2017.03.046

92. Yang L, Zheng LY, Tian Y, Zhang ZQ, Dong WL, Wang XF, et al. C6 Ceramide Dramatically Enhances Docetaxel-Induced Growth Inhibition and Apoptosis in Cultured Breast Cancer Cells: A Mechanism Study. *Exp Cell Res* (2015) 332(1):47–59. doi: 10.1016/j.yexcr.2014.12.017

93. Fu M, Wan F, Li Z, Zhang F. 4sc-202 Activates Ask1-Dependent Mitochondrial Apoptosis Pathway to Inhibit Hepatocellular Carcinoma Cells. *Biochem Biophys Res Commun* (2016) 471(2):267–73. doi: 10.1016/j.bbrc.2016.01.030

94. Zhang R, Li G, Zhang Q, Tang Q, Huang J, Hu C, et al. Hirsutine Induces Mptp-Dependent Apoptosis Through Rock1/Pten/Pi3k/Gsk3β Pathway in Human Lung Cancer Cells. *Cell Death Dis* (2018) 9(6):598. doi: 10.1038/s41419-018-0641-7

95. Ghosh JC, Siegelin MD, Dohi T, Altieri DC. Heat Shock Protein 60 Regulation of the Mitochondrial Permeability Transition Pore in Tumor Cells. *Cancer Res* (2010) 70(22):9888–93. doi: 10.1158/0008-5472.Can-10-2225

96. Xie YC, Zha JH, Sang YH, Yin H, Xu GQ, Zhen J, et al. Apmk Activation by Asp4132 Inhibits Non-Small Cell Lung Cancer Cell Growth. *Cell Death Dis* (2021) 12(4):365. doi: 10.1038/s41419-021-03655-2

97. Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM. P53 Opens the Mitochondrial Permeability Transition Pore to Trigger Necrosis. *Cell* (2012) 149(7):1536–48. doi: 10.1016/j.cell.2012.05.014

98. Chen W, Feng L, Nie H, Zheng X. Andrographolide Induces Autophagic Cell Death in Human Liver Cancer Cells Through Cyclophilin D-Mediated Mitochondrial Permeability Transition Pore. *Carcinogenesis* (2012) 33(11):2190–8. doi: 10.1093/carcin/bgs264

99. Brenner C, Subramaniam K, Pertuiset C, Pervaiz S. Adenine Nucleotide Translocase Family: Four Isomers for Apoptosis Modulation in Cancer. *Oncogene* (2011) 30(8):883–95. doi: 10.1038/onc.2010.501

100. Tavecchio M, Lisanti S, Lam A, Ghosh JC, Martin NM, O’Connell M, et al. Cyclophilin D Extramitochondrial Signaling Controls Cell Cycle Progression and Chemokine-Directed Cell Motility. *J Biol Chem* (2013) 288(8):5553–61. doi: 10.1074/jbc.M112.433045

101. Wu PK, Hong SK, Park JI. Mortalin Depletion Induces Mek/Erk-Dependent and Ant/Cytp-Mediated Death in Vemurafenib-Resistant B-Raf(V600e) Melanoma Cells. *Cancer Lett* (2021) 502:25–33. doi: 10.1016/j.canlet.2020.12.044

102. Wu PK, Hong SK, Chen W, Becker AE, Gundry RL, Lin CW, et al. Mortalin (Hspa9) Facilitates Braf-Mutant Tumor Cell Survival by Suppressing Ant3-Mediated Mitochondrial Membrane Permeability. *Sci Signal* (2020) 13(622): eaay1478. doi: 10.1126/scisignal.aay1478

103. Chen SH, Li DL, Yang F, Wu Z, Zhao YY, Jiang Y. Gemcitabine-Induced Pancreatic Cancer Cell Death Is Associated With Mst1/Cyclophilin D Mitochondrial Complexation. *Biochimie* (2014) 103:71–9. doi: 10.1016/j.biochi.2014.04.004

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhang, Liu, Zhou, He, Wang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.